KRT17 and invasive breast carcinoma: In agreement with the aforementioned findings, in our study, KRT17 is over-expressed in the head and neck squamous cell carcinoma, esophageal carcinoma, bladder urothelial carcinoma, pancreatic adenocarcinoma as well as cervical squamous cell carcinoma and endocervical adenocarcinoma, whilst it is down-regulated in breast invasive carcinoma (Table 1).